Non-Clinical Topics   /   Pharmacy

Kadcyla Approved for Treatment of HER2-positive Metastatic Breast Cancers

By US Medicine

SAN FRANCISCO – The FDA has approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin┬« (trastuzumab) and a taxane chemotherapy. Kadcyla is the fourth medicine from Genentech to receive FDA approval for people with advanced cancers within the past two years. An antibody-drug conjugate (ADC), Kadcyla is the first FDA-approved ADC for treating HER2-positive mBC. Kadcyla is made up of the antibody, trastuzumab, and the chemotherapy, DM1, joined together using a stable linker. Kadcyla combines the mechanisms of action of both trastuzumab and DM1, and it is the first Genentech ADC approved by the FDA.


Related Articles

Shulkin Ousted, White House Physician Nominated for VA Secretary

WASHINGTON — After several weeks of speculation regarding his future in the Trump Administration, VA Secretary David Shulkin, MD’s tenure came to an abrupt end on March 28.

Military E-Prescriptions Exceed 50% Goal Set Three Years Ago

FALLS CHURCH, VA — As of January 2018, 54% of prescriptions filled by MTFs were submitted electronically, exceeding the initial goal of 50% set when the e-prescribing program first rolled out three years ago.


U.S. Medicine Recommends


More From fda news

FDA News

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

FDA News

Long-Acting Insulins Approved by FDA

Vascular Events Lead to Stroke About a Fourth of the Time. INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help... View Article

FDA News

FDA Approves Option for Schizophrenia, Bipolar Treatment

Vascular Events Lead to Stroke About a Fourth of the Time. INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help... View Article

FDA News

New DHA Screening Process Brings Drug Compounding Costs to 2% of April Levels

Vascular Events Lead to Stroke About a Fourth of the Time. INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help... View Article

FDA News

FDA Approves Tecfidera for Treatment of Relapsing MS

Vascular Events Lead to Stroke About a Fourth of the Time. INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up